Cytokinetics (CYTK) Current Deferred Revenue (2011 - 2026)

Cytokinetics (CYTK) has reported Current Deferred Revenue for 11 consecutive years, with $1.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Deferred Revenue fell 96.84% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (down 96.84% YoY), while the FY2025 annual figure was $1.6 million, down 96.92% from the prior year.
• Current Deferred Revenue rose to $1.7 million in Q1 2026 per CYTK's latest filing, from $1.6 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $52.4 million in Q4 2024 and bottomed at $1.3 million in Q2 2025.
• Historically, Current Deferred Revenue has averaged $18.5 million across 3 years, with a median of $1.6 million in 2025.
• Annual changes were most pronounced in 2025 — Current Deferred Revenue tumbled 96.92% — and 2026, when it sank 96.84%.
• Cytokinetics' Current Deferred Revenue stood at $52.4 million in 2024, then sank by 96.92% to $1.6 million in 2025, then rose by 2.54% to $1.7 million in 2026.
• Business Quant data shows CYTK's Current Deferred Revenue at $1.7 million in Q1 2026, $1.6 million in Q4 2025, and $1.6 million in Q3 2025.